<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00252772</url>
  </required_header>
  <id_info>
    <org_study_id>D6160C00026</org_study_id>
    <nct_id>NCT00252772</nct_id>
  </id_info>
  <brief_title>GALLANT 2 Tesaglitazar vs. Placebo</brief_title>
  <official_title>A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is a 24-week randomized, double-blind, parallel-group, multi-center, placebo-controlled&#xD;
      study of tesaglitazar (0.5 and 1 mg) in patients with type 2 diabetes, not adequately&#xD;
      controlled on diet and lifestyle advice alone during the run-in period. The study comprises a&#xD;
      6-week single-blind placebo run-in period followed by 24-week treatment period and a 3-week&#xD;
      follow-up period.&#xD;
&#xD;
      The study design of GALLANT 2 is identical to GALLANT 22; the blinded study data from GALLANT&#xD;
      2 will be transferred to the GALLANT 22 database and will be analyzed together with the data&#xD;
      from GALLANT 22 clinical study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The development program has been terminated&#xD;
  </why_stopped>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the following variables from baseline to the end of the randomized treatment period:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid parameters (triglyceride [TG], total cholesterol, high-density lipoprotein cholesterol [HDL C], non-HDL C, low-density lipoprotein cholesterol [LDL C], apolipoproteins [Apo] A-I, Apo B, Apo CIII, free fatty acids, lipoprotein particle size and c</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein, LDL C/HDL C ratio and Apo B/Apo A-I ratio</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose (FPG), homeostatic model assessment, insulin, proinsulin, C-peptide</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor-alpha, intracellular adhesion molecule-1</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with microalbuminuria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist/hip ratio</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder analyses for HbA1c, FPG, TG, HDL C, non HDL C and LDL C according to pre-specified values</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching pre-specified target levels for HbA1c, FPG, TG, HDL C, non-HDL C and LDL C</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of tesaglitazar</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of tesaglitazar by assessment of adverse events , laboratory values, electrocardiogram,, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes: Well-Being Questionnaire (W BQ12)</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesaglitazar</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary and Lifestyle counseling</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of a written informed consent&#xD;
&#xD;
          -  Men or women who are &gt;=18 years of age&#xD;
&#xD;
          -  Female patients: postmenopausal, hysterectomized, or if of childbearing potential,&#xD;
             using a reliable method of birth control&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes&#xD;
&#xD;
          -  Treated with diet alone or treatment with a single oral antidiabetic agent or low&#xD;
             doses of two oral antidiabetic agents&#xD;
&#xD;
          -  Drug-naïve (ie, no use of antidiabetic drug[s] for at least 24 weeks prior to visit&#xD;
             1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  New York Heart Association heart failure Class III or IV&#xD;
&#xD;
          -  Treatment with chronic insulin&#xD;
&#xD;
          -  History of hypersensitivity or intolerance to any peroxisome proliferator-activated&#xD;
             receptor agonist (like Actos or Avandia), fenofibrate, metformin or&#xD;
             3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)&#xD;
&#xD;
          -  History of drug-induced myopathy or drug-induced creatine kinase elevation, liver&#xD;
             enzyme elevations, neutropenia (low white blood cells)&#xD;
&#xD;
          -  Creatinine levels above twice the normal range&#xD;
&#xD;
          -  Creatine kinase above 3 times the upper limit of normal&#xD;
&#xD;
          -  Received any investigational product in other clinical studies within 12 weeks&#xD;
&#xD;
          -  Any clinically significant abnormality identified on physical examination, laboratory&#xD;
             tests or electrocardiogram, which in the judgment of the investigator would compromise&#xD;
             the patient's safety or successful participation in the clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Galida Medical Science Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanko</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Imatra</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kokkola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mikkeli</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pattijoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pietarsaari</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ödet</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>November 10, 2005</study_first_submitted>
  <study_first_submitted_qc>November 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>April 21, 2009</last_update_submitted>
  <last_update_submitted_qc>April 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

